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SHORT COMMUNICATION
Carcinoma of the cervix uteri: an assessment of the relationship of
tumour proliferation to prognosis
D.J. Cole', D.C. Brown2, E. Crossley', C.J. Alcock' & K.C. Gatter2
'Department ofRadiotherapy and Oncology, Churchill Hospital, Oxford; 2Nuffield Department ofPathology, John Radcliffe
Hospital, Oxford, UK.
Summary The aim of this study was to ascertain whether assessing the growth fraction of cervical carcinoma
of 28 patients, using antibody Ki-67, would be of value in clinical practice. The results showed no relationship
between growth fraction and age, clinical stage, lymph node involvement or short term (3-5 years) survival.
The most important feature determining survival in carcin-
oma of the cervix is thought to be the clinical stage of the
tumour at presentation (Kottmeier, 1971). Other clinical
parameters of importance include the size of the primary
tumour (Montana et. al., 1983) and involvement of the pelvic
lymph nodes at Wertheim's hysterectomy (Alcock & Toplis,
1987). It has also been suggested that younger patients have
a poorer prognosis (Hall & Monaghan, 1983), although this
has been disputed (Russell et al., 1987). Despite these para-
meters, cases with an apparently good prognosis often do
badly and vice versa (Wiernik, 1986).
The value of histological and immunological features in
predicting the clinical course remains controversial. Studies
of cell size, tumour differentiation or presence of antigenic
markers each have their advocates (Ng & Atkin, 1973; van
Nagell et al., 1977; Bobrow et al., 1986) and opponents
(Crissman et al., 1985; Goellner, 1976; Wells et al., 1986;
Fray et al., 1984).
The measurement of tumour growth fraction offers a
potentially valuable approach to predicting clinical behaviour
and may also assist in optimising radiation dose schedules
(Wilson et al., 1988a).
Monoclonal antibody, Ki-67, identifies a nuclear associated
antigen in human cells which is present in all stages of the
cell cycle except Go (Gerdes et al., 1984a; Brown & Gatter,
1990; Gerdes et al., 1991). A good correlation has been
shown between the immunocytochemical labelling of cell
nuclei with Ki-67 and other methods of assessing cell pro-
liferation, e.g. flow cytometry and autoradiography (Gerdes
et al., 1984a). Preliminary studies of lymphoma (Gerdes et
al., 1984b; Hall et al., 1988), breast cancer (Gerdes et al.,
1986) and carcinoma of the lung (Gatter et al., 1986) have
shown that Ki-67 gives a rapid and reliable estimate of the
tumour growth fraction.
In a previous study it was shown (Brown et al., 1988) that
there was little correlation between conventional histological
classification of carcinoma of the cervix and the growth
fraction as measured by Ki-67. This suggested that Ki-67
immunostaining might provide an independent means of
assessing clinical behaviour in cervical neoplasia. The present
study was therefore undertaken to determine the value of
estimating tumour growth fraction immunocytochemically in
a number of patients with carcinoma of the cervix followed
clinically for periods between 3-5 years.
The pathological material for this study was obtained from
an unselected series of 28 patients with carcinoma of the
cervix (6 adenocarcinomas, 22 squamous cell carcinoma) who
were referred to the Radiotherapy Department in Oxford
between 1984-86. The patients required dilatation of the
cervix, currettage and cervical biopsy as part of their diag-
nostic work-up and staging. Informed consent was obtained.
Immunocytochemistry was performed using the alkaline
phosphatase: anti-alkaline phosphatase (APAAP) technique
(Cordell et al., 1984). The assessment of tumour cell pro-
liferation using the monoclonal antibody Ki-67 and the assig-
nation of tumour grade and type have been described pre-
viously (Brown et al., 1988).
The clinical information collected included age, FIGO
(International Federation of Obstetrics and Gynaecology)
stage, nodal status at Wertheim's hysterectomy and survival.
Surgical confirmation of nodal status in the majority of
patients was possible because of the policy of combined
modality treatment using pre-operative intracavitary irradia-
tion followed by Wertheim's hysterectomy.
Statistical analysis was performed using Student's t-test
and Fisher's exact probability test (Swinscow, 1983). Calcula-
tion of survival curves was achieved using Microsoft Excel
(version 2.2) software.
The clinical and pathological information for the 28
patients investigated in this study is summarised in Table I.
The probabilities of a relationship existing between the
parameters recorded in this study are shown in Table II. As
can be seen there was no significant relationship between the
percentage of tumour cells stained by Ki-67 or the conven-
tional histological grade and any of the clinical parameters.
For the purpose of this analysis, the FIGO stages of the
tumours were combined into two groups: stage I and stage
II-IV and the conventional histology grades into two
groups: well and moderately differentiated (grades I + II) and
poorly differentiated (grade III). This allowed the subgroups
to be of a sufficient size for analysis. For ten patients, the
nodal status was not established pathologically because they
had disease that was too advanced for Wertheim's hysterec-
tomy. Seven out of ten in this group were in FIGO stage
III-IV and the other three were stage II. Because this group
had relatively advanced disease, they were combined with the
node positive patients for analysis.
Patients were divided into two groups, depending on the
amount of Ki-67 staining. Those cases having a Ki-67 count
greater than 30% (the mean of all the Ki-67 values) were
considered as high grade tumours and those with Ki-67
values less than the mean were considered low grade. The
survival curves of these two groups are shown below (Figure
1). The small number of cases in each group prohibits mean-
ingful statistical analysis.
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Table I Clinical and pathological data of the patients investigated in this study
Patient
number
1
2
3
4
S
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Age
27
58
39
60
43
42
77
72
65
26
64
61
38
69
54
54
74
57
30
48
61
46
34
33
62
68
49
80
FIGO
stage
II
II
I
II
III
I
II
III
III
IV
IV
I
I
I
I
I
II
I
II
III
II
I
III
II
Node status
Negative
Unknown
Negative
Unknown
Unknown
Negative
Negative
Unknown
Unknown
Unknown
Unknown
Negative
Negative
Negative
Positive
Negative
Negative
Negative
Positive
Negative
Unknown
Positive
Negative
Negative
Unknown
Negative
Negative
Unknown
% staining
Ki-67
antigen
18
46
42.5
33
41
20
22.5
27.5
41
30
26.5
23
47
32
25
24
29.5
19.5
45
24.5
35
40.5
28.5
40
14.5
23
30
39
Histological
grade
III
Unknown
I
Unknown
III
III
III
III
II
III
III
I
II
III
II
II
I
II
III
III
III
II
III III
II
II I
I
Outcome
Dead
Dead
Alive
Alive
Alive
Alive
Alive
Dead
Alive
Dead
Dead
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Dead
Alive
Dead
Dead
Alive
Alive
Dead
Alive
Alive
Dead Dead 4
Duration of
survival
(mths)
9
17
53
61
27
40
42
4
49
5
8
51
57
61
42
55
55
69
9
53
18
27
59
46
61
55
54
4
Table II Tests of statistical significance comparing clinical and
pathological information
Age FIGO stage Nodal status Outcome
% Staining
with Ki-67 0.3la 0.95b 0.09b 0.21b
Conventional
histology 0.67b 0.42c 0.28c 0.16c
The numbers are the probabilities (Pvalues). aCorrelation test; "Two
sample t-test; cFisher test (one tailed).
0
a-
._ 5z
Q0
0
Months
Figure 1 Survival curves of patients with cervical carcinoma of
low and high proliferative grades ( <30% and >30%) as assess-
ed by antibody Ki-67. AD- Low Ki-67, -*- High Ki-67.
Clinical evaluation and diagnostic imaging often fail to
indicate the local extent of tumour in carcinoma of the cervix
(Alcock & Toplis, 1987). Because staging is less than 100%
reliable, some patients receive more, and others less, treat-
ment than is necessary. The curability of stage I carcinoma of
the cervix is 75% (Wiernik, 1986) and therefore toxicity
related to treatment, particularly if it affects subsequent
quality of life, is an important factor in deciding the dose of
radiation and the volume of tissue to be treated. Stage I
patients who relapse often do so because of clinically occult
disease in pelvic lymph nodes and represent a group of
patients whose treatment would be different if they could be
identified.
Ki-67 immunostaining has been shown to have potential
prognostic value in previous studies of malignant disease.
Hall et al. (1988) found that patients with histologically low
grade lymphoma and a relatively high Ki-67 count (>5%), had a worse survival than those with a count below 5%. In
contrast, those patients with histologically high grade disease
with Ki-67 counts of more than 80% had a better survival
than those below that figure. One explanation for this might be that rapidly proliferating lesions are more vulnerable to
chemotherapy.
The present authors have previously undertaken similar
studies of carcinoma of the cervix comparing pathological features with Ki-67 immunostaining (Brown et al., 1988). There is little evidence that conventional histological features
bear much relationship to prognosis or clinical response in
cervical cancer. The fact therefore that Ki-67 immunostaining appeared to give a grading of these tumours independent of
histology indicated that clinical follow up of such patients might be valuable.
However in the present study of 28 patients treated for
carcinoma of the cervix and followed for 3-5 years no
relationship could be demonstrated between Ki-67 immuno-
staining and survival (Figure 1) or other accepted prognostic
parameters such as FIGO staging or pelvic lymph node
involvement at hysterectomy.
There are several possible reasons for this. The number of
cells labelled by Ki-67 varies within the tumour and a single biopsy from a large lesion may not be representative of the
whole. In this study, the actual invasive edge of the tumour
was often not sampled and it may well be that such factors
are critical for determining clinical behaviour. Furthermore, half of the patients in this study had tumours at FIGO stage
II or more and hence are at a late stage in the development of a disease which is generally believed to have a long pre-invasive component. Measurement of proliferation rates
in patients with earlier lesions, e.g. carcinoma in situ or
micro-invasive carcinoma might therefore yield a more pro- fitable group for prospective study. Finally, the failure to
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show Ki-67 as an independent discriminator between low and
high risk groups may be, in part, due to the relatively small
number of patients in this study (necessitated by the need to
recruit patients prospectively for fresh biopsy samples). A
larger study might reveal an influence on prognosis that went
undetected in the current investigation.
The inability of Ki-67 to act as a prognostic indicator in
cervical carcinoma is in keeping with the findings of Tunge-
kar et al. (1991) who studied 187 lung tumours and found
that Ki-67 did not provide any additional prognostic inform-
ation to that already obtained from histological assessment.
Indeed both of these studies (lung tumours and cervical
carcinoma) are in keeping with the general impression given
in the review of this antibody (Brown & Gatter, 1990) that
the role of Ki-67 in predicting a tumour's clinical behaviour
is most convincingly demonstrated in lymphoproliferative
disorders and connective tissue diseases rather than carcin-
omas.
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